Hydrumedical S.A. (HYD) team is composed by a urologist and biomaterials scientists that will revolutionise the treatment of ureteral disorders. Hydrustent is a biodegradable, hydrogel-based, soft, lubricated, and flexible stent....
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto HYDRUSTENT
Duración del proyecto: 24 meses
Fecha Inicio: 2023-11-20
Fecha Fin: 2025-11-30
Líder del proyecto
HYDRUMEDICAL SA
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
2M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Hydrumedical S.A. (HYD) team is composed by a urologist and biomaterials scientists that will revolutionise the treatment of ureteral disorders. Hydrustent is a biodegradable, hydrogel-based, soft, lubricated, and flexible stent. These properties prevent bacterial adhesion (>80% of the stent-related complications) and encrustation development. Nowadays, the application of stents requires a 2nd removal procedure, a burden for patients and healthcare systems. Hydrustent is homogeneously degraded by the urine flow within 7-10 days, eliminating the need of further interventions for its removal. Hydrustent will bring huge health benefits for patients and reduce up to 60% of treatment costs (4.3B€ savings for the health system in EU+US). Validated by the urology community, with a global Ureteral Stents Market raising (~604M€ by 2030), if Hydrustent project is successfully implemented, we intend to reach the EU market in 2024 with profits amounting to 25M€, 5 years after product launch.